Clinical and metabolic effects of drospirenone-estradiol in menopausal women: A prospective study

Climacteric

Volumn 14, Issue 1, 2011, Pages 18-24

  Gambacciani, M ^a   Rosano, G ^b   Cappagli, B ^a   Pepe, A ^a   Vitale, C ^b   Genazzani, A R ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

blood pressure; hormone replacement therapy; insulin sensitivity; Menopause; quality of life

Indexed keywords

CALCIUM; DROSPIRENONE PLUS ESTRADIOL; INSULIN; SEX HORMONE;

ANTHROPOMETRY; ANXIETY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT TOOL; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEAR; FEMALE; HOMEOSTASIS; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOW DRUG DOSE; METABOLIC PARAMETERS; MOOD; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; SEXUAL BEHAVIOR; SLEEP; SLEEP DISORDER; SUBSTITUTION THERAPY; SYSTOLIC BLOOD PRESSURE; VASOMOTOR DISORDER; WAIST CIRCUMFERENCE; WORLD HEALTH ORGANIZATION;

ALDOSTERONE ANTAGONISTS; ANDROSTENES; ANXIETY; BLOOD PRESSURE; DEPRESSION; ESTRADIOL; ESTROGENS; FEAR; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEXUAL BEHAVIOR; SLEEP DISORDERS; SYSTOLE; WAIST CIRCUMFERENCE;

EID: 79951659138     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2010.520099     Document Type: Article

References (31)

1. Peltonen M, Lundberg V, Huhtasaari F, Asplund K. Marked improvement in survival after acute myocardial infarction in middle-aged men but not in women. The Northern Sweden MONICA study 1985-94. J Intern Med 2000;247:579-87 (Pubitemid 30318061)
2. Mosca L, Appel LJ, Benjamin EJ, et al. Summary of the American Heart Association's evidence-based guidelines for cardiovascular disease prevention in women. Arterioscler Thromb Vasc Biol 2004;24:394-6 (Pubitemid 38326128)
3. Board of the International Menopause Society, Pines A, Sturdee DW, Birkhäuser MH, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-94 (Pubitemid 46752441)
4. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33 (Pubitemid 34761611)
6. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J Am Med Assoc 2007;297:1465-77 (Pubitemid 46556472)
7. Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. Climacteric 2007;10:508-26 (Pubitemid 350211299)
8. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006;15:35-44 (Pubitemid 43192860)
9. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804 (Pubitemid 38951954)
10. Oelkers W. Drospirenone - a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 2000;5(Suppl 3):17-24 (Pubitemid 32173575)
11. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
12. Schürmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004;7:189-96 (Pubitemid 38951701)
13. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716-27 (Pubitemid 41669124)
14. Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004;7:103-11 (Pubitemid 38367168)
15. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005;18:797-804 (Pubitemid 40745265)
16. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979-84 (Pubitemid 41377417)
17. Rapkin AJ, Sorger SN, Winer SA. Drospirenone/ethinyl estradiol. Drugs Today 2008;44:133-45 (Pubitemid 351587981)
18. Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7:45-54
19. Hunter M. The Women's Health Questionnaire (WHQ): the development, standardization and application of a measure of midaged women's emotional and physical health. Qual Life Res 2000;9:733-8 (Pubitemid 32181937)
20. Genazzani AR, Nicolucci A, Campagnoli C, et al., for the Progetto Donna Qualità della Vita Working Group; Novo Nordisk Italia. Validation of Italian version of the Women's Health Questionnaire: assessment of quality of life of women from the general population and those attending menopause centers. Climacteric 2002;5:70-7 (Pubitemid 34309857)
21. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of lowdose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003;44:157-63
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19 (Pubitemid 15018832)
23. Casanova G, Radavelli S, Lhullier F, Spritzer PM. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause. Fertil Steril 2009;92:605-12
24. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23 (Pubitemid 40138015)
25. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
26. Cho GJ, Lee JH, Park HT, et al. Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. Menopause 2008;15:524-9
27. Genazzani AR, Gambacciani M, Simoncini T, Schneider HP; International Menopause Society. HRT in climacteric and aging brain. Climacteric 2003;6:188-203
28. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001;13:453-64 (Pubitemid 32590928)
29. Gerber LM, Sievert LL, Warren K, Pickering TG, Schwartz JE. Hot flashes are associated with increased ambulatory systolic blood pressure. Menopause 2007;14:308-15 (Pubitemid 46673483)
30. Gambacciani M, Ciaponi M, Cappagli B, Benussi B, De Simone L, Genazzani AR. Climacteric modifications in body weight and fat tissue distribution. Climacteric 1999;2:37-44 (Pubitemid 29253924)
31. Amigoni S, Morelli P, Parazzini F, Chatenoud L. Determinants of elevated blood pressure in women around menopause: results from a cross-sectional study in Italy. Maturitas 2000;34:25-32 (Pubitemid 30015984)